The results of the CONFIRM trial testing #terlipressin for #HRS were presented at the #LiverMtg19 this week.
COI: CONFIRM investigator, consultant for Mallinckrodt #hepatorenal #AKI

@AASLDtweets dr. Ghany @NIDDKgov delivers the hepatitis debrief. When it comes to #HCC Risk reduction, tenofovir and entecavir are like coke and pepsi #LiverMtg19

@AASLDtweets if you’re wondering where #LiverMtg20 is...you found it #LiverMtg19

@AASLDtweets by far the best and most stimulating presentations of #LiverMtg19 today. Saving the best for last!

@AASLDtweets dr. Llovet @BCLC_group @idibaps @MountSinaiLiver no proven adjuvant therapies for #HCC after curative resection. Major unmet need #LiverMtg19

@AASLDtweets dr. Llovet: molecular classification of #HCC broadly includes non proliferation (TGF-B) vs proliferation (B-catenin) driven tumors #LiverMtg19

@AASLDtweets dr. Llovet: #HCC is intermediate mutagenicity (about 60 mutations/per tumor) and unfortunately most are undruggable #LiverMtg19

@AASLDtweets dr. Llovet: about 1 million new cases of liver cancer worldwide by 2025. Feels like we’re already there! #LiverMtg19

@AASLDtweets Schiff State of the art lecture delivered by dr. Llovet on molecular pathogenesis and management of #HCC #LiverMtg19

@AASLDtweets is #PSC an infectious disease? Probably not and nothing I heard today convinced me otherwise #LiverMtg19

@AASLDtweets dr. Oh: “loss of microbial diversity” in persons with NAFLD-cirrhosis. #LiverMtg19

@AASLDtweets dr. Gawrieh: #saroglitazar (PPAR-alpha, gamma) reduces ALT as early as week 4 and about 40% reduce MRI-PDFF by >30% at highest dose. I would really like to get excited about PPARs in #NASH but I can’t. #LiverMtg19

@AASLDtweets dr. Hassanein: DUR-928 seems to lower bilirubin in severe alcoholic hepatitis. Lille score drops by day 7. Interesting but numbers too small to draw conclusions and no placebo #LiverMtg19

@AASLDtweets 50% of subjects who took lonafarnib/lambda IFN and ritonavir achieve undetectable HDV RNA after 24 weeks. Some GI effects and inc. bilirubin requiring dose reduction #LiverMtg19

@AASLDtweets #LiverMtg19 continues the recent tradition of multiple late breakers and high profile presentations all in the last 4 hours of the meeting. I get why every meeting is doing this but many miss out...

@AASLDtweets looking forward to the last day of #LiverMtg19 or as I like to call it DD (debrief day)

@AASLDtweets #terlipressin is clearly not a silver bullet for type 1 HRS and there are definitely significant AEs to contend with. Biggest disappointment in my mind was 31% reversal rate which I thought was closer to 40-45% (but different definitions) #LiverMtg19

@AASLDtweets #terlipressin caused more abdominal pain, resp. failure and more discontinuations. 2/200 had intestinal ischemia. #LiverMtg19

@AASLDtweets dr. Wong: #terlipressin meets primary endpoint of verified type 1 HRS reversal (31% vs 15% for placebo). Less patients need dialysis after transplant compared to placebo. No impact of survival #LiverMtg19

@AASLDtweets dr. Sanyal: >50% itch on higher dose of #tropifexor tho only 7% discontinue and LDL goes up. People seem to lose weight too. All this muddies the waters quite a bit #LiverMtg19

@AASLDtweets dr. Sanyal: #tropifexor (non bile acid FXR agonist) shows >30% reduction in MRI-PDFF in 64% at 12 wks. If you bank on 30% drop in PDFF, that’s pretty good! #livermtg19

@AASLDtweets dr. Sanyal: REVITA-2 study shows 53% reaching 30% reduction in MRI-PDFF. 1 duodenal perforation for under 150 studied. Safety? Durability beyond 6 mos? #livermtg19

@AASLDtweets dr. Sanyal: duodenal mucosal surfacing (DMR) is basically lifting duodenal mucosa with saline then circumferentially ablating it resulting in metabolic improvement. Studied vs. sham in NASH #livermtg19

@AASLDtweets I do not understand why we continue to pursue avenues focused on insulin sensitization and de novo lipogenesis in #NASH #justsayin’ #livermtg19

@AASLDtweets dr harrison: MSDC-0602K at its highest dose has a modest (if any) improvement in fibrosis and #NASH resolution compared to placebo. Does improve glucose metabolism. #livermtg19

@AASLDtweets dr. Harrison: #MSDC-0602K basically works at the Pyruvate carrier step of the Krebs cycle. End result among other things is slow down of de novo lipogenesis #livermtg19

@AASLDtweets dr. Lucey: we now call it “alcohol use disorder” not alcoholic liver disease #AUD #LiverMtg19

@AASLDtweets dr. Lindor: Urso is NOT an effective treatment for itching related to #PBC (or itching from chronic liver disease in general). Common point of confusion #LiverMtg19

@AASLDtweets dr. Lindor: if you suspect auto-immune hepatitis overlap with #PBC (usually ALT>5xULN) then you need to confirm with a liver biopsy #livermtg19

Dr. Heimbach: @AASLDtweets sez if you have #HCC with macrovascular invasion/extrahepatic spread then systemic therapy is recommended. Not controversial. #LiverMtg19